Ccr5 Antagonist - Pharma

Relevant Publications

HIV and gp120-induced lipid droplets loss in hepatic stellate cells contribute to profibrotic profile.

Issue Release: 2024

Therapeutic inhibition of monocyte recruitment prevents checkpoint inhibitor-induced hepatitis.

Issue Release: 2024

Cenicriviroc, a CCR2/CCR5 antagonist, promotes the generation of type 1 regulatory T cells.

Issue Release: 2024

α-Synuclein triggers cofilin pathology and dendritic spine impairment via a PrP-CCR5 dependent pathway.

Issue Release: 2024

In ovarian cancer maraviroc potentiates the antitumoral activity and further inhibits the formation of a tumor-promoting microenvironment by trabectedin.

Issue Release: 2024

CX3CR1 deficiency promotes resolution of hepatic ischemia-reperfusion injury by regulating homeostatic function of liver infiltrating macrophages.

Issue Release: 2024

Cancer-associated fibroblasts promote enzalutamide resistance and PD-L1 expression in prostate cancer through CCL5-CCR5 paracrine axis.

Issue Release: 2024

Analysing the Combined Effects of Radiotherapy and Chemokine Receptor 5 Antagonism: Complementary Approaches to Promote T Cell Function and Migration in Oesophageal Adenocarcinoma.

Issue Release: 2024

Characterization of a CXCR4 antagonist TIQ-15 with dual tropic HIV entry inhibition properties.

Issue Release: 2024

Involvement of CCR5 on interstitial macrophages in the development of lung fibrosis in severe asthma.

Issue Release: 2024

CCR5 antagonist maraviroc alleviates doxorubicin-induced neuroinflammation and neurobehavioral deficiency by regulating NF-κB/NLRP3 signaling in a breast cancer mouse model.

Issue Release: 2024

Flagellin Restricts HIV-1 Infection of Macrophages through Modulation of Viral Entry Receptors and CC Chemokines.

Issue Release: 2024

Blockade of CCR5 T Cell Accumulation in the Tumor Microenvironment Optimizes Anti-TGF-β/PD-L1 Bispecific Antibody.

Issue Release: 2024

Cancer-associated fibroblasts promote enzalutamide resistance and PD-L1 expression in prostate cancer through CCL5-CCR5 paracrine axis.

Issue Release: 2024

A novel antagonist of the CCL5/CCR5 axis suppresses the tumor growth and metastasis of triple-negative breast cancer by CCR5-YAP1 regulation.

Issue Release: 2024

Cenicriviroc suppresses and reverses steatohepatitis by regulating macrophage infiltration and M2 polarization in mice.

Issue Release: 2024

Duloxetine protected indomethacin-induced gastric mucosal injury by increasing serotonin-dependent RANTES expression and activating PI3K-AKT-VEGF pathway.

Issue Release: 2024

A New Application for Cenicriviroc, a Dual CCR2/CCR5 Antagonist, in the Treatment of Painful Diabetic Neuropathy in a Mouse Model.

Issue Release: 2024

CCR2/CCR5 antagonist cenicriviroc reduces colonic inflammation and fibrosis in experimental colitis.

Issue Release: 2024

Blockade of CCR5 and CXCR3 attenuates murine acute graft-versus-host disease through modulating donor-derived T cell distribution and function.

Issue Release: 2024

What is an Abbreviated New Drug Application (ANDA)?

What is Transitional Care?

What is Pharma?

What is Medication Management?

Why is Regulatory Approval Important?

What Causes Adverse Drug Events?

How Does Cellular Stress Impact Drug Development?

What Role Does Technology Play?

How Can Pharma Companies Improve Patient Education?

What is Regulatory Approval?

Partnered Content Networks

Relevant Topics